Clinical trialNCT06431594RecruitingPhase 1Interventional

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

SponsorGlaxoSmithKlineEnrollment675NeoplasmsSolid Tumors

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

65 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Gsk Investigational Site
Cipoletti Rio Negro, Argentina
Andres Guercovich
Recruiting
Gsk Investigational Site
Ciudad de Buenos Aires, Argentina
Mercedes Tamburelli
Recruiting
Gsk Investigational Site
La Plata, Argentina
Fabiana Marmissolle
Recruiting
Gsk Investigational Site
Rosario, Argentina
Cristina Nasurdi
Recruiting

Australia

Gsk Investigational Site
Blacktown, New South Wales, Australia
Phuong Dinh
Recruiting
Gsk Investigational Site
Macquarie University, New South Wales, Australia
Dhanusha Sabanathan
Recruiting

Belgium

Gsk Investigational Site
Leuven, Belgium
Toon van Gorp
Recruiting

Brazil

Gsk Investigational Site
Barretos, Brazil
Ana Suellen Carneiro
Recruiting
Gsk Investigational Site
Goiânia, Brazil
Ruffo de Freitas Junior
Recruiting
Gsk Investigational Site
Rio de Janeiro, Brazil
Andreia Melo
Recruiting

Canada

Gsk Investigational Site
Ottawa, Ontario, Canada
John Hilton
Recruiting
Gsk Investigational Site
Toronto, Ontario, Canada
Stephanie Lheureux
Recruiting
Gsk Investigational Site
Toronto, Ontario, Canada
Helen MacKay
Recruiting
Gsk Investigational Site
Montreal, Quebec, Canada
Kim Ma
Recruiting
Gsk Investigational Site
Montreal, Quebec, Canada
Diane Provencher
Recruiting

Finland

Gsk Investigational Site
Helsinki, Finland
Johanna Maenpaa
Recruiting
Gsk Investigational Site
Helsinki, Finland
Katriina Jalkanen
Recruiting
Gsk Investigational Site
Tampere, Finland
Synnove Staff
Recruiting

France

Gsk Investigational Site
Lyon, France
Isabelle Ray Coquard
Recruiting
Gsk Investigational Site
Saint-Herblain, France
Jean-Sebastien Frenel
Recruiting
Gsk Investigational Site
Villejuif, France
Alexandra LEARY
Recruiting

Italy

Gsk Investigational Site
Aviano PN, Italy
Michele Bartoletti
Recruiting
Gsk Investigational Site
Milan, Italy
Giuseppe Curigliano
Recruiting
Gsk Investigational Site
Milan, Italy
Domenica Lorusso
Recruiting
Gsk Investigational Site
Naples, Italy
Adriano Gravina
Recruiting
Gsk Investigational Site
Roma, Italy
Vanda Salutari
Recruiting

Japan

Gsk Investigational Site
Saitama, Japan
Kosei Hasegawa
Recruiting
Gsk Investigational Site
Shizuoka, Japan
Kentaro Yamazaki
Recruiting
Gsk Investigational Site
Tokyo, Japan
Shigehisa Kitano
Recruiting

Netherlands

Gsk Investigational Site
Amsterdam, Netherlands
Marloes G.J. van Rijn-van Dongen
Recruiting

South Korea

Gsk Investigational Site
Gyeonggi-do, South Korea
Myong Cheol Lim
Recruiting
Gsk Investigational Site
Seoul, South Korea
Jeong-Won Lee
Recruiting
Gsk Investigational Site
Seoul, South Korea
Jung-Yun Lee
Recruiting
Gsk Investigational Site
Seoul, South Korea
Jae-Weon Kim
Recruiting

Spain

Gsk Investigational Site
Barcelona, Spain
Lorena Fariñas Madrid
Recruiting
Gsk Investigational Site
Córdoba, Spain
María Jesús Rubio Perez
Recruiting
Gsk Investigational Site
Girona, Spain
Pilar Barretina
Recruiting
Gsk Investigational Site
Madrid, Spain
Andres Redondo Sanchez
Recruiting
Gsk Investigational Site
Madrid, Spain
Victor Moreno
Recruiting
Gsk Investigational Site
Madrid, Spain
Eva Maria Guerra Alia
Recruiting

25 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Mocertatug rezetecan

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 2 Jul 2024
Primary completion: 22 Sept 2027
Completion: 31 Dec 2029
Last update posted: 25 Jun 2026
Registered enrollment: 675
Registry id: NCT06431594

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-513860-25

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.